Advertisement

Drugs & Therapy Perspectives

, Volume 23, Issue 1, pp 10–13 | Cite as

Managing urinary incontinence in women depends on whether symptoms are associated with stress, urgency or both

Disease Management
  • 34 Downloads

References

  1. 1.
    Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21 (2): 167–78PubMedCrossRefGoogle Scholar
  2. 2.
    Hashim H, Abrams P. Pharmacological management of women with mixed urinary incontinence. Drugs 2006; 66 (5): 591–606PubMedCrossRefGoogle Scholar
  3. 3.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20 (6): 327–36PubMedGoogle Scholar
  4. 4.
    Coyne KS, Zhou Z, Thompson C, et al. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003 Nov; 92(7): 731–5PubMedCrossRefGoogle Scholar
  5. 5.
    Monz B, Pons ME, Hampel C, et al. Patient-reported impact of urinary incontinence: results from treatment seeking women in 14 European countries. Maturitas 2005 Nov; 52 Suppl. 2: 24–34CrossRefGoogle Scholar
  6. 6.
    Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004 Mar; 63(3): 461–5PubMedCrossRefGoogle Scholar
  7. 7.
    Turner DA, Shaw C, McGrother CW, et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004 Jun; 93 (9): 1246–52PubMedCrossRefGoogle Scholar
  8. 8.
    Abrams P, Andersson KE, Brubaker L, et al. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. Paris: Health Publication Ltd, 2005: 1589–630Google Scholar
  9. 9.
    Nygaard IE, Kreder KJ, Lepic MM, et al. Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence. Am J Obstet Gynecol 1996 Jan; 174 (1 Pt 1): 120–5PubMedCrossRefGoogle Scholar
  10. 10.
    Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64(15): 1643–56PubMedCrossRefGoogle Scholar
  11. 11.
    Andersson KE, Appell R, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, et al. editors. Incontinence. Paris: Health Publication Ltd, 2005: 809–54Google Scholar
  12. 12.
    Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 Aug; 62(2): 237–42PubMedCrossRefGoogle Scholar
  13. 13.
    Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003 Jul; 189(1): 98–101PubMedCrossRefGoogle Scholar
  14. 14.
    Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003 Jul; 189(1): 98–101PubMedCrossRefGoogle Scholar
  15. 15.
    Bump R, Yalcin I, Voss S. The effect of duloxetine dose escalation and tapering on the incidence of adverse events (AE) in women with stress urinary incontinence (SUI) [abstract no. 116]. Neurourol Urodyn 2005 Sep; 24(5/6): 582–3Google Scholar
  16. 16.
    Lilley Research Laboratories. Safety data on Cymbalta (duloxetine hydrochloride): hepatic effects. [online]. Available from URL: http://www.fda.gov/medwatch Accessed 2006 Sep 18]
  17. 17.
    Khullar V, Hill S, Laval KU, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004 Aug; 64(2): 269–74PubMedCrossRefGoogle Scholar
  18. 18.
    Kreder KJ, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int 2003 Sep; 92(4): 418–21PubMedCrossRefGoogle Scholar
  19. 19.
    Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168(2): 580–6PubMedCrossRefGoogle Scholar
  20. 20.
    Kelleher C, Cardozo L, Kobashi K, et al. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunt 2005 Nov; 8: 1–7Google Scholar
  21. 21.
    Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004 Oct; 83(10): 892–7PubMedGoogle Scholar
  22. 22.
    Robinson D, Cardozo L, Akeson M, et al. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 2004 May; 93(7): 996–1000PubMedCrossRefGoogle Scholar
  23. 23.
    Ishiko O, Ushiroyama T, Saji F, et al. β2-Adrenergic agonists and pelvic floor exercises for female stress incontinence. Int J Gynaecol Obstet 2000 Oct; 71(1): 39–44PubMedCrossRefGoogle Scholar
  24. 24.
    Lin HH, Sheu BC, Lo MC, et al. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 1999 Oct; 106(10): 1089–92PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations